Stryker Corporation : Stryker Corporation Announces Pricing of $1.0 Billion Senior Notes Offering

 Stryker Corporation : Stryker Corporation Announces Pricing of $1.0 Billion
                            Senior Notes Offering

Stryker Corporation (NYSE:SYK) announced today that it has priced an offering
to sell $600 million of senior unsecured notes due 2018 (the "2018 Notes") and
$400 million of senior unsecured notes due 2043 (the "2043 Notes"). The 2018
Notes will bear interest at 1.300% per year and, unless previously redeemed,
will mature on April 1, 2018. The 2043 Notes will bear interest at 4.100% per
year and, unless previously redeemed, will mature on April 1, 2043.

The Company intends to use the net proceeds from the offering for working
capital and other general corporate purposes, including acquisitions, stock
repurchases and other business opportunities.

Barclays, BofA Merrill Lynch, and Goldman Sachs are acting as active joint
book-running managers for the offering. This offering was made pursuant to a
prospectus supplement to the Company's prospectus, dated February 28, 2013,
filed as part of the Company's effective shelf registration statement. Copies
of the preliminary prospectus supplement and accompanying prospectus relating
to the notes may be obtained by contacting the joint book-running managers:
Barclays Capital Inc., Attention: Prospectus Department, 745 Seventh Avenue,
New York, New York 102825, or by calling 888-603-5847, or by emailing; Goldman, Sachs & Co., Attention:
Prospectus Department, 200 West Street, New York, New York 10282, or by
calling 866-471-2526, or by emailing; and
Merrill Lynch, Pierce, Fenner & SmithIncorporated, Attention: Prospectus
Department, 222 Broadway, 11^th Floor, New York, New York 10038, or by calling
800-294-1322, or by emailing

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy any securities nor will there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or other jurisdiction.

This press release contains information that includes or is based on
forward-looking statements within the meaning of the federal securities law
that are subject to various risks and uncertainties that could cause our
actual results to differ materially from those expressed or implied in such
statements. Such factors include, but are not limited to: weakening of
economic conditions that could adversely affect the level of demand for our
products; pricing pressures generally, including cost-containment measures
that could adversely affect the price of or demand for our products; changes
in foreign exchange markets; legislative and regulatory actions; unanticipated
issues arising in connection with clinical studies and otherwise that affect
U.S. Food and Drug Administration approval of new products; changes in
reimbursement levels from third-party payors; a significant increase in
product liability claims; the ultimate total cost with respect to the
Rejuvenate and ABG II matter; the impact of investigative and legal
proceedings and compliance risks; resolution of tax audits; the impact of the
federal legislation to reform the United States healthcare system and the 2.3
percent medical device excise tax; changes in financial markets; changes in
the competitive environment; our ability to integrate acquisitions, including
the acquisition of Trauson Holdings Company Limited; and our ability to
realize anticipated cost savings as a result of workforce reductions and other
restructuring activities. Additional information concerning these and other
factors are contained in our filings with the U.S. Securities and Exchange
Commission, including our Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q.

Stryker is one of the world's leading medical technology companies and is
dedicated to helping healthcare professionals perform their jobs more
efficiently while enhancing patient care. The Company offers a diverse array
of innovative medical technologies, including reconstructive, medical and
surgical, and neurotechnology and spine products to help people lead more
active and more satisfying lives.


For media inquiries please contact:
Yin Becker, Stryker Corporation, 201-831-5000 or

For investor inquiries please contact:
Katherine A. Owen, Stryker Corporation, 269-385-2600 or


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Stryker Corporation via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.